Nicholas Durham

Nicholas Durham possesses extensive experience in translational medicine with a focus on hematology and oncology. As Executive Director of Hematology R&D Translational Medicine at AstraZeneca from March 2019 to May 2025, Nicholas managed cross-site operations and led initiatives in hematological-oncology, emphasizing biomarker strategies and data-driven clinical translation. Previous roles include Sr. Director of Translational Medicine, where leadership of teams focused on oncology products was paramount, and Associate Director, overseeing Phase I asset strategies. Prior to AstraZeneca, Nicholas served as Translational Medicine Lead at MedImmune, developing strategies for advancing T cell therapies and oncolytic viruses. Academic background includes a PhD in Immunology from Johns Hopkins University, where research contributions led to multiple publications in diverse disease areas. Additionally, Nicholas has experience in education and property management.